Abstract
Background We embedded a pragmatic, cluster-randomised trial into Uganda’s national campaign to distribute long-lasting insecticidal nets (LLINs) in 2020–2021, comparing LLINs treated with pyrethroids plus the synergist piperonyl butoxide (PBO), to LLINs treated with pyrethroids plus pyriproxyfen, an insect growth regulator.
Methods Target communities surrounding public health facilities (clusters, n=64), covering 32 high-burden districts not receiving indoor residual spraying, were included. Clusters were randomised 1:1 in blocks of two by district to receive: (1) pyrethroid-PBO LLINs (PermaNet 3.0, n=32) or (2) pyrethroid-pyriproxyfen LLINs (Royal Guard, n=32). LLINs were delivered from 7 November 2020 to 26 March 2021 and malaria outcome data were collected until 31 March 2023. Estimates of malaria incidence in residents of all ages (the primary outcome) were generated for each cluster from enhanced health facility surveillance data. At 12- (24 November 2021 to 1 April 2022) and 24-months (23 November 2022 to 21 March 2023) post-LLIN distribution, cross-sectional community surveys were conducted in randomly selected households (at least 50 per cluster, 3,200 per survey).
Findings In the two years following LLIN distribution, 186,364 episodes of malaria were diagnosed in cluster residents during 398,931 person-years of follow-up. Malaria incidence after 24-months was lower than at baseline in both arms (pyrethroid-PBO: 465 vs 676 episodes per 1000 person-years; pyrethroid-pyriproxyfen: 469 vs 674 episodes per 1000 person-years); but the difference between the arms was not statistically significant (incidence rate ratio 1.06, 95% confidence interval [CI] 0.91– 1.22, p=0.47). Two years post-distribution, ownership of at least one LLIN for every two household residents was low in both arms (41.1% pyrethroid-PBO vs 38.6% pyrethroid-pyriproxyfen). Parasite prevalence in children aged 2-10 years was no different between the arms in either survey and similar results were observed for prevalence of anaemia in children aged 2-4 years.
Interpretation The effectiveness of pyrethroid-PBO LLINs and pyrethroid-pyriproxyfen LLINs was no different in Uganda, but two years after mass distribution, LLIN coverage was inadequate.
Funding US National Institutes for Health, Bill and Melinda Gates Foundation
Trial registration NCT04566510. Registered 28 September 2020, https://clinicaltrials.gov/ct2/show/NCT04566510
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04566510. Registered 28 September 2020, https://clinicaltrials.gov/ct2/show/NCT04566510
Funding Statement
This project was funded primarily by the US National Institutes for health, with additional funding from the Bill and Melinda Gates Foundation. The content of the manuscript is solely the responsibility of the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research included in this trial was conducted under two study protocols. The Implementation Project Pilot Study covered enumeration of the target areas and estimation of malaria incidence using health facility surveillance data. This project was approved by the Makerere University School of Medicine Research & Ethics Committee (SOMREC, Ref 2019-087), the Ugandan National Council of Science and Technology (UNCST, Ref HS 2659), and the University of California, San Franciso Human Research Protection Program Institutional Review Board (UCSF Ref 19-27957). The LLINEUP2 trial protocol provided approval for the full trial, including the cross-sectional surveys, and was approved by the Makerere University School of Medicine Research & Ethics Committee (SOMREC Ref 2020-193), Ugandan National Council for Science and Technology (UNCST Ref HS1097ES), the University of California San Francisco Human Research Protection Program Institutional Review Board (UCSF Ref 20-31769), and the London School of Hygiene & Tropical Medicine Ethics Committee (LSHTM Ref 22615). Prior to enrolment into the clinical surveys, written informed consent was obtained from a parent or guardian for all children aged less than 18 years and the child provided assent if they were aged 8 years or older.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
samuelgonahasa{at}gmail.com, jnamuganga{at}idrc-uganda.org, mnassali{at}idrc-uganda.org, cmaiteki{at}gmail.com, inabende{at}idrc-uganda.org, adrienne.epstein{at}ucsf.edu, Katherine.snyman{at}lshtm.ac.uk, jnankabirwa{at}yahoo.co.uk, opigojimmy{at}gmail.com, martin.donnelly{at}lstmed.ac.uk, grant.dorsey{at}ucsf.edu, mkamya{at}infocom.co.ug, sarah.staedke{at}lstmed.ac.uk
Data Availability
De-identified participant data and a data dictionary defining each field in the set will be made publicly available at the time of publication on the ClinEpiDB website
